Michael DiFiore
Stock Analyst at Evercore ISI
(0.85)
# 4,065
Out of 4,703 analysts
9
Total ratings
55.6%
Success rate
-7.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael DiFiore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $392 → $649 | $541.08 | +19.95% | 2 | May 7, 2026 | |
| VTVT vTv Therapeutics | Initiated Coverage: Buy | $44 | $33.35 | +31.93% | 1 | Mar 12, 2026 | |
| ALT Altimmune | Initiated Coverage: Buy | $25 | $3.42 | n/a | 1 | Aug 22, 2025 | |
| SKYE Skye Bioscience | Initiated Coverage: Buy | $10 | $1.86 | n/a | 1 | Aug 15, 2025 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $55 | $110.19 | n/a | 2 | May 15, 2025 | |
| ATRA Atara Biotherapeutics | Downgraded: Hold | n/a | $9.76 | n/a | 1 | Nov 9, 2023 | |
| CLYM Climb Bio | Initiated Coverage: Buy | n/a | $15.52 | n/a | 1 | Sep 8, 2021 |
Madrigal Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $392 → $649
Current: $541.08
Upside: +19.95%
vTv Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $33.35
Upside: +31.93%
Altimmune
Aug 22, 2025
Initiated Coverage: Buy
Price Target: $25
Current: $3.42
Upside: n/a
Skye Bioscience
Aug 15, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $1.86
Upside: n/a
Halozyme Therapeutics
May 15, 2025
Reiterated: Buy
Price Target: $55
Current: $110.19
Upside: n/a
Atara Biotherapeutics
Nov 9, 2023
Downgraded: Hold
Price Target: n/a
Current: $9.76
Upside: n/a
Climb Bio
Sep 8, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $15.52
Upside: n/a